Ocular Therapeutix Inc (OCUL)
8.52
-0.26
(-2.96%)
USD |
NASDAQ |
Nov 21, 16:00
8.89
+0.37
(+4.34%)
Pre-Market: 20:00
Ocular Therapeutix Enterprise Value: 980.09M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 980.09M |
| November 20, 2024 | 1.021B |
| November 19, 2024 | 1.043B |
| November 18, 2024 | 1.007B |
| November 15, 2024 | 1.081B |
| November 14, 2024 | 1.200B |
| November 13, 2024 | 1.307B |
| November 12, 2024 | 1.307B |
| November 11, 2024 | 1.364B |
| November 08, 2024 | 1.379B |
| November 07, 2024 | 1.329B |
| November 06, 2024 | 1.354B |
| November 05, 2024 | 1.296B |
| November 04, 2024 | 1.249B |
| November 01, 2024 | 1.268B |
| October 31, 2024 | 1.290B |
| October 30, 2024 | 1.376B |
| October 29, 2024 | 1.411B |
| October 28, 2024 | 1.422B |
| October 25, 2024 | 1.386B |
| October 24, 2024 | 1.347B |
| October 23, 2024 | 1.342B |
| October 22, 2024 | 1.411B |
| October 21, 2024 | 1.422B |
| October 18, 2024 | 1.415B |
| Date | Value |
|---|---|
| October 17, 2024 | 1.378B |
| October 16, 2024 | 1.437B |
| October 15, 2024 | 1.243B |
| October 14, 2024 | 1.279B |
| October 11, 2024 | 1.173B |
| October 10, 2024 | 1.085B |
| October 09, 2024 | 1.097B |
| October 08, 2024 | 1.101B |
| October 07, 2024 | 1.126B |
| October 04, 2024 | 1.182B |
| October 03, 2024 | 1.087B |
| October 02, 2024 | 1.099B |
| October 01, 2024 | 1.060B |
| September 30, 2024 | 1.003B |
| September 27, 2024 | 960.84M |
| September 26, 2024 | 976.43M |
| September 25, 2024 | 985.79M |
| September 24, 2024 | 946.81M |
| September 23, 2024 | 926.54M |
| September 20, 2024 | 1.008B |
| September 19, 2024 | 1.017B |
| September 18, 2024 | 1.019B |
| September 17, 2024 | 973.32M |
| September 16, 2024 | 999.82M |
| September 13, 2024 | 1.011B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
128.53M
Minimum
Nov 16 2023
1.663B
Maximum
Dec 22 2020
549.17M
Average
407.95M
Median
Jan 10 2024
Enterprise Value Benchmarks
| 4D Molecular Therapeutics Inc | -132.53M |
| NovaBay Pharmaceuticals Inc | 2.798M |
| Palatin Technologies Inc | 15.96M |
| iBio Inc | 12.31M |
| Theriva Biologics Inc | -12.68M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -36.49M |
| Revenue (Quarterly) | 15.42M |
| Total Expenses (Quarterly) | 61.42M |
| EPS Diluted (Quarterly) | -0.22 |
| Gross Profit Margin (Quarterly) | 89.88% |
| Profit Margin (Quarterly) | -236.6% |
| Earnings Yield | -15.49% |
| Normalized Earnings Yield | -11.99 |